Results 191 to 200 of about 1,525,157 (341)
The Cost of the National Disability Insurance Scheme: Australia's Print‐Media Discourse
ABSTRACT This paper examines the way that Australian newspapers have framed the cost of the National Disability Insurance Scheme (NDIS). Introduced in 2013, the NDIS represented a major change in Australia's disability support policy, moving for the first time to a nationwide universal insurance model.
Meera Chinnappa +2 more
wiley +1 more source
Access To Dental Care Among People Newly Eligible For A Medicare Dental Benefit. [PDF]
Simon L, Daley N.
europepmc +1 more source
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery ...
Jens Tidemandsen +9 more
wiley +1 more source
Developing a pricing model for general medical consultation services among private consulting rooms in Harare, Zimbabwe. [PDF]
Gota C +3 more
europepmc +1 more source
Effect and Threshold of Endoscopic Findings for CRS Control Status and Long‐Term Outcome Prediction
ABSTRACT Background EPOS 2020 defined chronic rhinosinusitis (CRS) disease control using patient symptoms and medication usage but endoscopic findings were considered optional. The effect of adding endoscopic features, an appropriate threshold, and their association with present or future symptom control have not been studied.
Steven Chun‐Kang Liao +14 more
wiley +1 more source
Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
American Journal of Hematology, EarlyView.
Rong Wang +9 more
wiley +1 more source
ABSTRACT Background Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health‐related quality of life and posing a safety hazard. Methods WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo ...
Joaquim Mullol +14 more
wiley +1 more source
Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population. [PDF]
Roth JA +9 more
europepmc +1 more source
Essays on higher education and research : capacities, tuitions fees and international mobility
Jonas Didisse
openalex +1 more source

